There is evidence from several randomized controlled clinical trials (RCTs) that the rates of severe and symptomatic hypoglycemia are different among various insulin treatment regimens, favoring long-acting insulin compared to premixed or short acting insulin use in type 2 diabetes [2], [3], [4]. The gene discussed is INS; the disease is type 2 diabetes mellitus.